QQ客服 官方微博 反馈留言

	Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
	Sun, Yan; Cheng, Ying; Hao, Xuezhi; Wang, Jie; Hu, Chengping; Han, Baohui; Liu, Xiaoqing; Zhang, Li; Wan, Huiping; Xia, Zhongjun
刊名	BMC CANCER
	2016
卷号	16
关键词	Amrubicin Cisplatin Etoposide ED-SCLC Randomized clinical trial Chinese
ISSN号	1471-2407
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3541542
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Sun, Yan,Cheng, Ying,Hao, Xuezhi,et al. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer[J]. BMC CANCER,2016,16.
APA	Sun, Yan.,Cheng, Ying.,Hao, Xuezhi.,Wang, Jie.,Hu, Chengping.,...&Luo, Xiaoyan.(2016).Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.BMC CANCER,16.
MLA	Sun, Yan,et al."Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer".BMC CANCER 16(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。